Innovative Bispecific Nanobody Targeting CD22 and CD3 Complex for Next-Generation Cancer Immunotherapy

VHH-P610 is a cutting-edge bispecific nanobody designed to target both CD22 molecule (CD22) and CD3 Complex (T Cell Receptor Complex). This novel humanized antibody construct is currently in the Biological Testing stage, offering a promising approach for cancer treatment. By simultaneously engaging the CD22 molecule (CD22), a key marker on B cells, and CD3 Complex (T Cell Receptor Complex), an essential component of T cell activation, VHH-P610 is poised to harness the immune system for targeted tumor cell elimination.

Licensing Opportunity

VHH-P610 is available for out-licensing opportunities. We welcome strategic collaborations and partnering discussions to further advance this innovative bispecific nanobody program toward addressing critical needs in cancer therapy.

Development Phase

Modality

VHH-P610 is a bispecific T-cell engager antibody comprising a single domain antibody (nanobody) directed against human CD22 and a single-chain variable fragment engineered to bind CD3. Expressed in human embryonic kidney cells, this modular structure combines the benefits of nanobody technology—including compact size and enhanced tissue penetration—with robust targeting precision. The structural simplicity and stability of nanobodies allow improved access to tumor microenvironments and reduced non-specific binding, making VHH-P610 particularly suited for challenging cancer indications where efficient immune engagement is critical.

Target

CD22 and CD3 Complex are highly validated immunological targets in cancer therapy. CD22 is a B-cell restricted surface antigen involved in regulating cellular signaling, predominantly expressed on mature B lymphocytes and most B-cell malignancies. CD3 Complex, a component of the T cell receptor, is fundamental for T cell activation and cytotoxic responses. Therapeutically, targeting CD22 enables selective engagement of B cell-derived tumors, while redirecting T cells via CD3 Complex leads to potent anti-tumor immunity. By dual engagement of CD22 and CD3 Complex, VHH-P610 capitalizes on the strategic intersection of tumor targeting and immune activation, underscoring its unique value within the immuno-oncology landscape.

Mechanism of Action

VHH-P610 functions as a bispecific T-cell engager that links malignant B cells expressing CD22 with cytotoxic T cells via CD3 Complex. The single domain antibody motif ensures high specificity for CD22, enabling precise targeting of cancer cells, while the anti-CD3 domain recruits and activates T cells within the tumor microenvironment. This proximity-driven mechanism triggers robust T cell activation, resulting in targeted killing of CD22-positive cancer cells. The nanobody platform incorporated in VHH-P610 offers additional therapeutic prospects, including the development of antibody-drug conjugates or other bispecific immunotherapies for a broad spectrum of cancer types.

Cancer

Cancer is a leading health challenge worldwide, representing a complex group of diseases characterized by uncontrolled cell growth and metastatic potential. According to established epidemiological studies, cancer cases continue to increase globally, with significant impacts on morbidity, mortality, and healthcare systems. Standard therapies include surgery, chemotherapy, radiotherapy, immunotherapy, and targeted treatments; however, these approaches often face challenges such as drug resistance, toxicity, and limited efficacy in certain patient subgroups. Many cancers remain refractory to current modalities, underlining an urgent need for innovative and more selective treatment options. VHH-P610, designed to orchestrate a precise immune attack by bridging CD22-positive tumor cells and T cells via CD3 Complex, holds promise to address these unmet needs, offering new hope for patients with difficult-to-treat malignancies and supporting the advancement of individualized immunotherapy.